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Andrea Schneider5,8, Stephanie Sherman9, Jun Yi Wang5,10 and Jin-Chen Yang5,6Abstract
The fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting a
subset of carriers of the FMR1 (fragile X mental retardation 1) premutation. Penetrance and expression appear to be
significantly higher in males than females. Although the most obvious aspect of the phenotype is the movement
disorder that gives FXTAS its name, the disorder is also accompanied by progressive cognitive impairment. In this
review, we address the cognitive neuropsychological and neurophysiological phenotype for males and females with
FXTAS, and for male and female unaffected carriers. Despite differences in penetrance and expression, the cognitive
features of the disorder appear similar for both genders, with impairment of executive functioning, working
memory, and information processing the most prominent. Deficits in these functional systems may be largely
responsible for impairment on other measures, including tests of general intelligence and declarative learning.
FXTAS is to a large extent a white matter disease, and the cognitive phenotypes observed are consistent with what
some have described as white matter dementia, in contrast to the impaired cortical functioning more characteristic
of Alzheimer’s disease and related disorders. Although some degree of impaired executive functioning appears to
be ubiquitous among persons with FXTAS, the data suggest that only a subset of unaffected carriers of the
premutation - both female and male - demonstrate such deficits, which typically are mild. The best-studied
phenotype is that of males with FXTAS. The manifestations of cognitive impairment among asymptomatic male carriers,
and among women with and without FXTAS, are less well understood, but have come under increased scrutiny.
Keywords: Fragile X-associated tremor/ataxia syndrome, FXTAS, FMR1, Fragile X, Executive function, Cognition
disorders, Fragile X premutationThe fragile X-associated tremor/ataxia syndrome (FXTAS)
is a late-onset neurodegenerative disorder associated with
trinucleotide (CGG) repeat expansions of the FMR1
(fragile X mental retardation 1) gene. The most obvious
signs and symptoms of FXTAS include action tremor,
ataxia, parkinsonism, and peripheral neuropathy, but cir-
cumscribed aspects of cognition are impaired as well.
FXTAS affects persons who have CGG expansions in the
premutation range (that is, 55–200 CGG repeats), as op-
posed to fragile X syndrome (FXS), which is associated
with the full mutation (over 200 CGG repeats) at FMR1.
FXTAS and FXS have very different phenotypes, the latter* Correspondence: jim.grigsby@ucdenver.edu
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unless otherwise stated.involving an early childhood-onset intellectual develop-
ment disorder, often with autistic features, while FXTAS
affects persons who previously were cognitively normal, in
the sixth or seventh decade of life.
The basic cognitive phenotype of FXTAS is relatively
well understood. However, at the time of the initial iden-
tification of FXTAS, it was thought that women who
carry the premutation might have little susceptibility to
the disorder, perhaps because of the presence of a nor-
mal allele among female heterozygotes. Penetrance, and
possibly expression, is significantly higher in males than
females, and because men with FXTAS were more readily
identified than females with FXTAS, they have been more
extensively studied, and more is known about the nature,
severity, and course of cognitive impairment among men.
The objective of this paper is to review the cognitive
neuropsychological phenotype of carriers of the fragile Xl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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who are clinically unaffected.
Review
Cognitive neuropsychological phenotype among males
with FXTAS
Since the first case reports [1], it has been apparent that
FXTAS is associated with a progressive decline in cogni-
tive functioning. Although deficits in several aspects of
cognition have been reported [2-4], the evidence appears
to support the idea that the primary disorder is a dis-
turbance of executive functioning (EF) [5]. The executive
functions represent an important subset of cognitive
abilities. In essence, EF is the capacity for the autono-
mous regulation of one’s own behavior and attention.
Fuster [6,7] maintains that EF represents the temporal
organization of behavior, allowing one to initiate pur-
poseful behavior, and to inhibit irrelevant or inappropri-
ate activity.
Early studies of FXTAS reported deficits in EF, work-
ing memory, speed/capacity of information processing
and learning [2,3,8]. The first systematic study of cogni-
tion essentially replicated the early results, and showed
that males with FXTAS ranged from high average
through severely impaired in these areas of functioning,
the group mean representing moderate impairment [4].
FXTAS patients performed significantly worse on several
EF measures than did a sample of controls.
General cognitive functioning among FXTAS patients
is typically impaired [2-4], although intelligence quo-
tient (IQ) scores are in the normal range. In the largest
study of men with FXTAS to date, mean Wechsler
Adult Intelligence Scale-III (WAIS-III) verbal and per-
formance (nonverbal) IQ scores were 106.6 and 97.7, re-
spectively [4]. Lower performance IQs may be a
function of the greater dependence of the nonverbal
scale on processing speed, working memory, and EF [5].
On the Mini Mental State Exam [9], a measure of gen-
eral mental status, the difference in mean scores of
FXTAS patients and controls was statistically, but not
clinically, significant (27.6 vs 29.2). Nevertheless, a subset of
individuals with FXTAS - most with advanced disease -
demonstrates frank dementia [10,11]. Performance on mea-
sures of declarative memory is impaired, likely reflecting
the effects of executive dysfunction (that is, problems with
active learning and active retrieval) rather than a primary
memory disorder.
Neither expressive nor receptive language appears to be
affected in FXTAS. Repetition, naming, reading, compre-
hension of complex material, and following spoken com-
mands differed little across groups. Performance on most
visuospatial measures was unimpaired, although men
with FXTAS performed more poorly than controls on
the WAIS-III Block Design subtest - probably inassociation with reduced processing speed and deficient
organizational ability [4,5].
In a study of functional status (basic physical function-
ing, activities of daily living, and instrumental activities
of daily living), men with FXTAS, but not unaffected
carriers, were impaired in all three functional areas. This
effect appeared to be mediated by both executive and
motor functioning [12].
It is not possible to localize the cognitive deficits of
FXTAS to a specific brain region. Although the event-
related brain potential (ERP) studies of Yang and col-
leagues [13,14] may implicate prefrontal cortex, EF is a
widely distributed functional system that also may be af-
fected by lesions of other areas, in particular the cerebel-
lum [15,16]. To a large extent, FXTAS is a white matter
disease [17-19], and the cognitive phenotype observed
among men with FXTAS is similar to what has been
called white matter dementia [16,20,21], in which the ex-
tent of executive deficits is correlated with the burden of
white matter abnormalities distributed throughout the
brain [22].
Cognitive neuropsychological phenotype among females
with FXTAS
The manifestation of neuropsychological signs and
symptoms in female carriers can be diverse with low
penetrance of FXTAS and milder phenotypes than those
observed in males. Based on current diagnostic criteria,
estimates suggest that as few as 8 to 16 % of female car-
riers will develop FXTAS [23,24]. Moreover, in compari-
son with males, the onset of FXTAS for females tends to
occur later in life, and is anatomically less severe, with a
lower penetrance of middle cerebellar peduncle and
pontine white matter hyperintensities, less brain atro-
phy, and less severe white matter disease overall [25,26].
This milder phenotype is thought to stem from protect-
ive mechanisms associated with X-inactivation and hor-
monal differences [27-29]. However, this notion does
not have full support [23].
Although studies of FXTAS among males suggest that
the presenting cognitive profile is predominantly one of
executive dysfunction, there is a dearth of research sys-
tematically examining the cognitive profile in females
with FXTAS. Indeed, existing studies have been inconsist-
ent in demonstrating interrelationships between neuro-
psychological profiles, imaging correlates, and standardized
clinical measures [25,30-32]. Recent neuropsychological
and neurophysiological studies have shown that females
with FXTAS present with executive dysfunction as the pri-
mary cognitive impairment, similar to the male cognitive
profile [32,33]. Most significantly, a neuropathological case
study series reported dementia in 4 of 8 autopsied female
carriers, in conjunction with an increased number of
intranuclear inclusions, suggesting that dementia may be
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FXTAS [34].
With regard to psychological symptoms in females with
FXTAS, neuroimaging studies have shown an association
between hippocampal abnormalities and anxiety in un-
affected carriers [35]. Although these results suggest that
females show mild early-onset neuropsychological pheno-
types irrespective of FXTAS, further research is needed to
understand the synergistic effects of age, psychological
vulnerability, and risk factors for FXTAS. Indeed, given
that prevalence rates for probable attention deficit hyper-
activity disorder (4.5 to 25%), anxiety (20.9 to 30%) and
depression (14.03 to 47.3%) far exceed the risk of FXTAS
(8 to 16%) in women [23,24,36-40], the molecular and
environmental factors contributing to gender-divergent
trajectories are yet to be fully characterized.
Neurophysiology of cognition in FXTAS
Much of what is known of the cognitive electrophysiology
of FXTAS patients has been found using the ERP tech-
nique. Cognitive ERPs, primarily representing the sum-
mated activity of post-synaptic potentials, offer an excellent
non-invasive measure for characterizing different stages of
cognitive processing due to their millisecond-level tem-
poral resolution [41].
While performing an auditory “oddball” task requiring
dual-response, a predominantly male group of partici-
pants with FXTAS had longer N100 latency and smaller
P200 amplitude than normal controls, indicating some
impairment of early-stage attention [13]. Furthermore,
these individuals showed decreased amplitude and pro-
longed latency of P300, a component believed to reflect
late-stage “controlled” attention and working memory
updating. P300 abnormalities in these FXTAS patients
were observed over fronto-central and parietal scalp,
and the frontal P300 measures correlated with executive
function test scores, working memory, FMR1 mRNA
level, and CGG repeat length [13]. The frontal P300 im-
pairments have been replicated in a second study includ-
ing 29 female FXTAS patients, with correlations also
obtained between P300 measures and executive function,
working memory, and information processing speed [32].
Therefore, it has been suggested [13,32] that abnormal
fronto-parietal attentional network dynamics may play an
important role in executive dysfunction, the primary cog-
nitive impairment in FXTAS [5].
Verbal memory and language processes in FXTAS also
have been probed via an ERP word repetition paradigm/
category judgment task, in which semantically congru-
ous (50%) and incongruous words are repeated after an
interval of between 10 and 140 seconds. This word repe-
tition paradigm was employed in the first published ERP
study of FXTAS [42], in which it was demonstrated that
FXTAS patients had a significantly reduced N400 wordrepetition effect (new-old incongruous words), an elec-
trophysiological marker of semantic processing load and
implicit memory previously shown to be sensitive to
early Alzheimer’s disease (AD) [43,44]. Unlike persons
with AD, however, FXTAS patients displayed a preserved
P600 word repetition effect (new-old congruous words)
that has been linked to episodic/declarative memory.
Yang and colleagues [45] examined a group of FXTAS
females and found a relatively normal N400 repetition
effect, but decreased N400 congruity effect (incongru-
ous-congruous new words), suggesting abnormal seman-
tic activation and/or semantic network disorganization,
which they attributed to executive dysfunction.
Electrophysiology has also been used to assess the effect-
iveness of potential pharmacologic treatments for FXTAS.
Because the N400 measures are sensitive to both FXTAS
and glutamatergic signaling [46], the method was utilized
to evaluate the treatment effects of memantine (an un-
competitive N-methyl-D-aspartate receptor antagonist ap-
proved for treatment of AD) in a substudy of the first
placebo-controlled, double-blind, randomized clinical trial
in FXTAS [47,48]. Results indicated a tendency toward lar-
ger N400 repetition effect amplitude after 12 months on
memantine, and patients who had increased N400 repeti-
tion effects showed the largest improvements in cued-
recall of the experimental verbal stimuli. Although the
main memantine trial in FXTAS showed no significant
treatment effects on the primary outcome measures of ex-
ecutive function and intention tremor [48], the ERP re-
sults suggest the need for further studies of memantine
and/or other therapeutic agents for this neurodegenerative
disorder, which currently has no proven therapies.
There is a paucity of other published studies on the
central neurophysiology of FXTAS, with a few case re-
port studies showing abnormal electroencephalogram
(for example, [49]). One noteworthy study of people
with FXTAS found decreased auditory prepulse inhib-
ition [50], an electromyography index of sensorimotor
gating also affected in FXS. Thus, abnormalities of the
frontal P300, N400 brain potentials, and prepulse inhib-
ition should all be considered putative electrophysio-
logical trait markers of the FMR1 premutation.
Cognition among unaffected male premutation carriers
The cognitive phenotype of unaffected male carriers of
the FMR1 premutation, although not as extensively
researched as that of males with FXTAS, is relatively
well understood. There is general agreement that some
males demonstrate a progressive age-related decline in
executive function skills that is greater than that dis-
played by males with a normal allele, matched on age
and IQ. In a series of published papers, Cornish and col-
leagues have isolated a subtle age-related decline of in-
hibitory control (as measured by the Haylings Task) and
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sequencing task [51-53]) that begins in early adulthood
and continues across the lifespan. Interestingly, males
with more than 100 CGG repeats may be especially at
risk for cognitive difficulties [51]. Grigsby and colleagues
[4] reported a similar profile of difficulties in executive
functioning, with unaffected carriers performing worse
than normal-allele controls on a composite measure of
EF, and on immediate and delayed recall on the Logical
Memory subtest of the Wechsler Memory Scale-III [54].
In addition, recent functional magnetic resonance im-
aging (fMRI) data indicate changes in prefrontal activity
in premutation carriers, irrespective of FXTAS diagnosis,
during performance of a working memory task [55].
These preliminary findings provide the first evidence to
suggest the involvement of specific brain regions associ-
ated with neural networks mediating EF among persons
in the premutation range, with or without FXTAS. How-
ever, several studies have failed to find differences in
cognitive performance between non-affected male car-
riers and typically developing males [56,57]. One possi-
bility is that relatively small samples sizes and variability
in age range and CGG repeat distribution across studies
may explain some of the discrepant findings.
To address this concern, Hunter and colleagues [58]
combined their samples to form a multi-center database
with 100 asymptomatic premutation males and 216 non-
carriers. In line with previous reports by Cornish and
Grigsby [4,5,51], analyses across shared measures of in-
hibition and working memory detected very subtle dif-
ferences (which were of minimal clinical significance) on
a measure of response inhibition (Stroop task), but on
no other cognitive measures. Taken together, current
findings provide evidence of a subtle, suboptimal level of
cognitive performance among a subset of unaffected car-
riers, involving mild deficits in inhibition and working
memory among a subset of male carriers, results which
are relatively consistent with earlier research [59-61].
Cognition among unaffected female premutation carriers
Although the presence of a neuropsychological phenotype
in unaffected female premutation carriers is controversial
[56,57], recent studies have shown that a subset of young
adult female carriers exhibit subtle deficits in executive
function and inhibitory control [33,37,62], visuospatial pro-
cessing [63,64], mathematical reasoning [65,66], and tasks
dependent on processing speed and working memory [32].
It has been argued that targeted, domain-specific measures
may more sensitively identify subtle neurocognitive deficits
than gross neuropsychological tests [67]. Indeed, more
targeted measures have identified enhanced psycho-
motor ability [68,69], motor programming deficits [70],
increased balance and memory problems [70,71], and
age- and CGG-dependent changes in the attentionaldemands of postural control [72]. Collectively, these
findings point to early at-risk phenotypic features sug-
gesting cerebellar dysfunction in a subgroup of female
premutation carriers; however, prospective longitudinal
studies will be needed to determine who will eventually
develop cognitive impairment and neurodegenerative
decline.
With regard to the neuropsychiatric phenotype, it has
been shown that a subgroup of women who carry the
FMR1 premutation, but who do not have FXTAS, may
also be more vulnerable to elevated symptoms of anxiety
and depression compared to the general population
[40,73,74]. At least in part this may be the result of genetic
variation (for example, CRHR1 polymorphisms and re-
lease of cortisol) moderating the stress of raising a child
with FXS [75,76]. However, one recent study has shown
that poorer inhibitory control and working memory are
associated with elevated social anxiety, depression, and
attention deficit hyperactivity disorder (predominantly
inattentive symptoms) among women with the FMR1
premutation [37].
These data are novel in that they indicate early changes
within frontally-mediated networks that may increase the
risk of neuropsychiatric dysfunction. However, evidence
for a contribution by other factors, such as expanded
CGG repeats, and reproductive history in depressive fe-
male carriers, and anxiety symptoms in female carriers,
has been inconsistent [37,75,76]. A recent study using
more detailed clinical interviews from the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition has
provided evidence that comorbid depressive and anxiety
disorders are associated with significantly expanded CGG
repeats, but not with reproductive or menstrual history
[77]. Thus, a complex set of factors may contribute to ex-
ecutive and neuropsychiatric dysfunction in female car-
riers, involving genetic and epigenetic factors, caregiver
burden, hormonal changes, and hypothalamic-pituitary-
adrenal axis function. The precise relationships among
these factors remain unclear.
Neuroimaging and cognition
The FMR1 gene and its protein product, fragile X mental
retardation protein (FMRP), are expressed in brain areas
important for high-level cognitive functioning [78,79].
Consequently, both subtle FMRP deficit and excessive
FMR1 mRNA may affect the brain during development
and aging in the FMR1 premutation, which ultimately lead
to the cognitive phenotype in FX premutation carriers.
Neuroimaging is a useful tool for non-invasive investiga-
tions of the impact of the FMR1 premutation on the brain
and neural substrates underlying the cognitive deficits.
Two main imaging modalities provide complementary in-
sights into the mechanisms: functional MRI, which exam-
ines brain activation during cognitive tasks, and structural
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ometry, and white matter structural integrity/connectivity.
Consistent with the FMRP expression profile in the
brain [80], both functional and structural MRI studies
have shown a dose–response of FMR1 gene expression
on brain regions important for working memory. In a
functional MRI study examining verbal working memory
in male and female premutation carriers [55], reduced
activation was observed in the right inferior frontal cor-
tex and left premotor cortex in both asymptomatic pre-
mutation carriers and carriers with FXTAS. Reduced
activation was found in right premotor/inferior frontal
cortex in the FXTAS group. The reduced activation in
the right inferior frontal cortex exhibited a significant
correlation with high lymphocytic FMR1 mRNA levels.
In a structural MRI study [80] of male premutation car-
riers, while individuals with FXTAS showed diffuse gray
matter loss most prominent in areas important for work-
ing memory (including prefrontal cortex, anterior cingu-
late cortex, and cerebellum) only the anterior cerebellar
vermis and hemisphere displayed volume loss in those
premutation carriers without FXTAS. Importantly, the
reduced gray matter density of the inferior frontal and
anterior cingulate cortices correlated significantly with
low working memory performance, and the reduced gray
matter density in the dorsomedial frontal cortex correlated
with long CGG repeat length in premutation carriers.
Functional MRI studies have also revealed differences in
brain activation in young adult premutation carriers
asymptomatic for FXTAS, even where subtle differences in
cognition cannot be measured by standard behavioral tech-
niques. In a study of delayed recall memory, premutation
carriers showed no deficits (relative to control participants)
in ability to recall pairings on an associative memory task a
day later, but were found to exhibit reduced left hippocam-
pal activation, and activity in the left hippocampus was also
negatively correlated with both FMR1 mRNA level and
psychiatric symptomatology [81].
Likewise, in a study examining magnitude estimation
processing, young asymptomatic adult carriers showed
significantly attenuated bilateral intraparietal sulcus (IPS)
activity that is commonly associated with the numerical
distance effect (that is, greater effort/brain activation when
the two displays to be compared are closer in numerosity),
despite comparable behavioral task performance with the
control group [82]. While both elevated FMR1mRNA and
increased CGG repeat expansion were associated with re-
duced IPS activation, the results of multiple regression
suggested that increased CGG repeat size was the primary
contributor to aberrant IPS function.
Molecular mechanisms of FXTAS
Although the data suggest that FXTAS may result from
a toxic gain of function associated with excessive levelsof FMR1 mRNA, the mechanism, and variables that in-
fluence it, remain unclear [83]. Although CGG repeat
size in the premutation range is a diagnostic indicator
and genetic marker for those who may develop FXTAS,
repeat length predicts only a portion of risk and severity
of FXTAS [84,85], and there are other yet unidentified
factors involved. Repeat length does not elucidate the
mechanism of cellular or central nervous system path-
ology, or the relationship of cellular pathology to clinical
disease.
Treatment of FXTAS
There are as yet no effective therapies for the treatment of
FXTAS. As noted previously, one 12-month randomized
controlled trial of memantine showed no difference from
placebo on measures of tremor severity and executive
functioning [48]. The limited literature is based largely on
case studies (for example, [86]) and treatment has largely
been directed toward symptom amelioration, with incon-
sistent results [87,88].
Conclusion
The cognitive phenotype of FXTAS for both sexes appears
to be characterized by a progressive impairment of execu-
tive functioning, working memory, and speed of infor-
mation processing. This is characteristic of the pattern
observed in fronto-cerebellar and white matter disease.
The degree of impairment may become severe, and in ad-
vanced stages people with FXTAS may have very signifi-
cant cognitive problems, even demonstrating problems
ordinarily associated with cortical disorders. The dysexe-
cutive syndrome that accompanies FXTAS appears to play
a significant role, along with the movement disorder, in a
significant decline in functional independence, and the de-
velopment of psychiatric symptomatology.
Among carriers of the FMR1 premutation who do not
have FXTAS, the data suggest that a subset of individuals
has mild executive impairment. Whether the cognitive def-
icits shown by these people indicate preclinical FXTAS, or
are neurodevelopmental features of a premutation pheno-
type, is uncertain, although some imaging data suggest that
both are possibilities [89]. Also unclear is whether cogni-
tive problems precede, follow, or are contemporaneous
with the onset of tremor and ataxia, and whether these
may be associated with neuropathologic and/or neurora-
diologic anomalies. Neurophysiologic and neuroimaging
data, in conjunction with neuropsychological examination,
may help to answer this question.
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